Opioid antagonists

J Pain Symptom Manage. 2014 Feb;47(2):341-52. doi: 10.1016/j.jpainsymman.2013.12.223.

Authors

Victoria Barnett¹, Robert Twycross², Mary Mihalyo³, Andrew Wilcock⁴

Affiliations

¹ University of Nottingham, Nottingham, United Kingdom.
² Oxford University, Oxford, United Kingdom.
³ Mylan School of Pharmacy, Duquesne University, Pittsburgh, Pennsylvania, USA.
⁴ University of Nottingham, Nottingham, United Kingdom. Electronic address: andrew.wilcock@nottingham.ac.uk.

PMID: 24512968
DOI: 10.1016/j.jpainsymman.2013.12.223

No abstract available

Publication types

Review

MeSH terms

Hospice Care
Humans
Internet
Naloxone* / administration & dosage
Naloxone* / adverse effects
Naloxone* / pharmacokinetics
Naloxone* / pharmacology
Naltrexone / administration & dosage
Naltrexone / adverse effects
Naltrexone / analogs & derivatives*
Naltrexone / pharmacokinetics
Naltrexone / pharmacology
Narcotic Antagonists* / administration & dosage
Narcotic Antagonists* / adverse effects
Narcotic Antagonists* / pharmacokinetics
Narcotic Antagonists* / pharmacology
Palliative Care
Quaternary Ammonium Compounds / administration & dosage
Quaternary Ammonium Compounds / adverse effects
Quaternary Ammonium Compounds / pharmacokinetics
Quaternary Ammonium Compounds / pharmacology

Substances

Narcotic Antagonists
Quaternary Ammonium Compounds
methylnaltrexone
Naloxone
Naltrexone